Targeting group II PAKs in cancer and metastasis

被引：67
作者：
Eswaran, Jeyanthy [1 ]
Soundararajan, Meera [1 ]
Knapp, Stefan [1 ,2 ]
机构：
[1] Univ Oxford, Struct Genom Consortium, Oxford OX3 7DQ, England
[2] Univ Oxford, Dept Clin Pharmacol, Oxford OX3 7DQ, England
来源：
CANCER AND METASTASIS REVIEWS | 2009年 / 28卷 / 1-2期
基金：
英国惠康基金;
关键词：
Group II PAKs; Cancer; Transformation; Drug designing; Specificity; Kinase inhibitors; ANCHORAGE-INDEPENDENT GROWTH; SERINE/THREONINE KINASE PAK4; INDUCED CELL-DEATH; P21-ACTIVATED KINASE; PROSTATE-CANCER; ACTIN DYNAMICS; PHOSPHORYLATION SITES; MORPHOLOGICAL-CHANGES; DISEASE PATHOGENESIS; NEURITE OUTGROWTH;
D O I：
10.1007/s10555-008-9181-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The p21 activated kinases (PAKs) play an essential role in cell signaling and control a variety of cellular functions including cell motility, survival, angiogenesis and mitosis. PAKs are important regulators in growth factor signaling, cytoskeletal reorganization and growth factor-mediated cell migration. Overexpression of PAKs has been detected in many cancers and linked to increased migration potential, anchorage independent growth and metastasis. Six isoforms of PAKs are expressed in human and based on their regulatory properties they have been classified into group I (PAK1-3) and group II (PAK4-6). Besides the well studied group I family, members of the group II PAKs also emerged as interesting targets for the development of new inhibitors for cancer therapy. The availability of high resolution crystal structures for all group II PAKs and their fundamentally different regulatory properties when compared with group I enzymes has opened new opportunities for rational drug designing strategies. In this review, we summarize the results of recent advances of the function of group II PAKs in tumorigenesis and metastasis as well as opportunities for exploring the unique catalytic domain dynamics of this protein family for the design of group II PAK specific inhibitors.
引用
收藏
页码：209 / 217
页数：9
相关论文
共 78 条
[1]   PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia [J].
Abo, A ;
Qu, J ;
Cammarano, MS ;
Dan, CT ;
Fritsch, A ;
Baud, V ;
Belisle, B ;
Minden, A .
EMBO JOURNAL, 1998, 17 (22) :6527-6540
[2]   Cryptic Rac-binding and p21Cdc42HS/Rac-activated kinase phosphorylation sites of NADPH oxidase component p67phox [J].
Ahmed, S ;
Prigmore, E ;
Govind, S ;
Veryard, C ;
Kozma, R ;
Wientjes, FB ;
Segal, AW ;
Lim, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (25) :15693-15701
[3]   A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF [J].
Ahmed, Tasneem ;
Shea, Kerry ;
Masters, John R. W. ;
Jones, Gareth E. ;
Wells, Claire M. .
CELLULAR SIGNALLING, 2008, 20 (07) :1320-1328
[4]   A tale of two Paks [J].
Arias-Romero, Luis E. ;
Chernoff, Jonathan .
BIOLOGY OF THE CELL, 2008, 100 (02) :97-108
[5]   The selectivity of protein kinase inhibitors: a further update [J].
Bain, Jenny ;
Plater, Lorna ;
Elliott, Matt ;
Shpiro, Natalia ;
Hastie, C. James ;
Mclauchlan, Hilary ;
Klevernic, Iva ;
Arthur, J. Simon C. ;
Alessi, Dario R. ;
Cohen, Philip .
BIOCHEMICAL JOURNAL, 2007, 408 :297-315
[6]   ADF/cofilin and actin dynamics in disease [J].
Bamburg, JR ;
Wiggan, OP .
TRENDS IN CELL BIOLOGY, 2002, 12 (12) :598-605
[7]   An essential role for NF-kappa B in preventing TNF-alpha-induced cell death [J].
Beg, AA ;
Baltimore, D .
SCIENCE, 1996, 274 (5288) :782-784
[8]   Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis? [J].
Birkenfeld, Joerg ;
Nalbant, Perihan ;
Yoon, Soon-Hee ;
Bokoch, Gary M. .
TRENDS IN CELL BIOLOGY, 2008, 18 (05) :210-219
[9]   PAK'n it in: Identification of a selective PAK inhibitor [J].
Bokoch, Gary M. .
CHEMISTRY & BIOLOGY, 2008, 15 (04) :305-306
[10]   Biology of the p21-activated kinases [J].
Bokoch, GM .
ANNUAL REVIEW OF BIOCHEMISTRY, 2003, 72 :743-781
12345678